Soligenix Inc represents values of innovation, integrity, and commitment to improving healthcare. The company's corporate philosophy revolves around developing and commercializing innovative therapeutics for unmet medical needs, particularly in the areas of oncology, rare diseases, and inflammation. Soligenix Inc strives to provide cutting-edge solutions to improve patient outcomes and enhance quality of life. With a strong focus on research and development, Soligenix Inc aims to create effective and safe therapies that address significant medical challenges. As a healthcare-focused company, Soligenix Inc is dedicated to promoting advancements in medical science and making a positive impact on global health.

Soligenix Inc is primarily present in the United States.

Some significant milestones achieved by Soligenix Inc include the successful completion of Phase 3 clinical trials for SGX301, its lead product candidate for the treatment of cutaneous T-cell lymphoma. The company also received two Fast Track designations from the U.S. FDA for SGX301, which highlights its potential to address unmet medical needs. Soligenix Inc has demonstrated positive results in multiple clinical studies, optimizing its drug delivery platforms and enhancing their commercialization potential. Furthermore, the company has made advancements in the development of innate defense regulator (IDR) technology, presenting promising results in various indications. Throughout its history, Soligenix Inc has continuously focused on advancing innovative therapies for unmet medical needs, making significant progress and positioning itself as a leader in biopharmaceutical research and development.

Soligenix Inc is a biopharmaceutical company specializing in developing and commercializing healthcare products. Founded in 1987, Soligenix Inc has a strong history of innovation and a commitment to improving patient outcomes. The company focuses on areas such as oncology, gastrointestinal diseases, and biodefense. Soligenix Inc has a broad portfolio of products in various stages of development, including advancements in cancer treatments and vaccines. With a dedicated team of experienced professionals and a reputation for excellence, Soligenix Inc continues to drive advancements in healthcare by delivering effective and life-changing therapies to patients worldwide.

The main competitors of Soligenix Inc in the market are pharmaceutical companies that operate in the same product and therapeutic areas. Soligenix Inc faces competition from industry leaders such as Amgen, Pfizer, and Novartis. These companies have similar offerings and target the same patient populations. However, Soligenix Inc differentiate themselves through their unique product pipeline and focus on developing innovative therapies. While competition remains intense, Soligenix Inc continues to strive for excellence and deliver value to its stakeholders.

Soligenix Inc is primarily active in the biotechnology and pharmaceutical industries.

Soligenix Inc operates as a biopharmaceutical company. The company is focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Soligenix Inc primarily focuses on two therapeutic areas: oncology and inflammatory diseases. The company's business model revolves around conducting research, clinical development, and seeking regulatory approvals for its drug candidates. Soligenix Inc aims to bring innovative treatments to market, addressing the needs of patients suffering from rare diseases.

KGV Soligenix iznosi −0,13.

Koeficijent cijene i prometa Soligenix iznosi 3,38.

AlleAktien Qualitätsscore za Soligenix je 2/10.

Promet očekivana Soligenix iznosi 519.690,00 USD.

Dobit očekivana Soligenix iznosi −13,94 mil. USD.

Soligenix Inc is a biopharmaceutical company specialized in the development and commercialization of therapeutics. The company has a wide product pipeline focused on three key areas: biodefense, orphan and rare diseases, and cancer. Soligenix has a successful track record in developing therapeutics based on technologies such as Controlled Release, Dendrimer technology, among others. The company has recently made several important advances in the development of new therapy options, including a collaborative impregnation licensing agreement with Nemaura Medical. The biodefense division of Soligenix aims to develop products and technologies that help reduce the impact of infections and diseases from biological threats. The company has three main products in this area: RiVax(TM), a vaccine against Rickettsia prowazekii to protect against typhus; CoVaccine HT(TM), a vaccine adjuvant used to improve immune response; SGX943 (still in preclinical phase), an anti-inflammatory agent for acute radiation injuries aiming to improve survival and recovery in nuclear accidents or other harmful radiation events. Soligenix focuses on developing therapies for orphan and rare diseases supported by legislation to treat rare diseases with no approved therapies. The company has a broad range of products in this area, some of the most advanced being: SGX301, a topical photodynamic therapy for the treatment of cutaneous T-cell lymphomas; SGX942, a treatment option for preventing and treating mucositis in cancer patients responding to chemotherapy; SGX203, the first and only oral system targeting the ferritin receptor effective in treating anemia in patients with chronic kidney disease. In the cancer division, Soligenix has launched several important projects for the development of treatment options for cancer patients. Some of the key products in this area include: SGX301, which can be used as a means of treating cancer cells associated with various types of cancer; SGX943, an anti-inflammatory drug aiming to support the body in recovering from the negative effects of radiation therapy in cancer treatments. All products share the goal of providing innovative solutions to improve people's lives and their chances of survival. Thanks to close collaboration with leading research institutions and organizations worldwide, Soligenix is well positioned to achieve a leading position in the biopharmaceutical industry.

Soligenix isplaćuje dividendu od 0 USD raspoređenu preko isplata godišnje.

Dividenda za Soligenix trenutno se ne može izračunati ili tvrtka ne isplaćuje dividendu.

ISIN od Soligenix je US8342233074.

WKN od Soligenix je A2AS7Q.

Oznaka burze tvrtke Soligenix je SNGX.

U posljednjih 12 mjeseci Soligenix je isplatio dividendu u iznosu od . To odgovara prinosu dividende od oko . Za sljedećih 12 mjeseci Soligenix će vjerojatno isplatiti dividendu u iznosu od 0 USD.

Trenutni prinos dividende od Soligenix iznosi .

Soligenix isplaćuje dividende kvartalno. One se isplaćuju u mjesecima .

Soligenix je isplatio dividendu svake godine u posljednjih 0 godina.

Za nadolazećih 12 mjeseci očekuje se isplata dividendi u iznosu od 0 USD. To odgovara dividendnom prinosu od 0 %.

Soligenix se pripisuje sektoru 'Zdravlje'.

Da bi primili posljednju dividendu od Soligenix od 18. 09. 2024. u iznosu od 0 USD, trebali ste imati dionicu u portfelju prije Ex-dana 18. 09. 2024..

Posljednja isplata dividende izvršena je 18. 09. 2024..

U godini 2023 su od Soligenix 0 USD isplaćene kao dividende.

Dividende od Soligenix isplaćuju se u USD.